| Expression pattern: |
UP |
| Associated gene: |
ETS1, HNRNPL, Ago2 |
| Associated microRNA: |
miR-646, miR-1200 |
| Biological function: |
promotes tumor cell proliferation and migration; inhibits apoptosis; promotes EMT; promotes tumor growth and metastasis; promotes enzalutamide resistance |
| Molecular mechanism: |
ceRNA mechanism: circPPFIA2 sponges miR-646 and miR-1200 to derepress ETS1; circPPFIA2 interacts with HNRNPL and associates with Ago2/RISC |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); metastasis (promotes); EMT (promotes); apoptosis (inhibits); cell cycle (promotes); p53 signaling (inhibits); ceRNA regulation (promotes); drug resistance (promotes) |
| Detected method: |
Q
H
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RNase R Treatment; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; RNA-seq; Bioinformatics Analysis; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; EdU Staining; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Survival Analysis; Clinical Sample Validation |
| Clinical significance: |
High circPPFIA2 is associated with advanced Gleason scores, accelerated biochemical recurrence, and reduced overall survival; proposed as a prognostic biomarker and therapeutic target |
| Description: |
circPPFIA2 is up-regulated in prostate cancer and promotes proliferation, migration/metastasis, EMT activation, and anti-apoptotic behavior. It functions mainly as a cytoplasmic ceRNA that sponges miR-646 and miR-1200, thereby upregulating ETS1 and driving enzalutamide resistance. |
| Confidence score: |
0.8933 |